These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 28304400

  • 1. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
    Ebisch RM, van der Horst J, Hermsen M, Rijstenberg LL, Vedder JE, Bulten J, Bosgraaf RP, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Massuger LF, Melchers WJ, Bekkers RL, Siebers AG.
    Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GA, Ridder R, Snijders PJ, Meijer CJ.
    Int J Cancer; 2015 May 15; 136(10):2361-8. PubMed ID: 25345358
    [Abstract] [Full Text] [Related]

  • 4. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
    Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R.
    Gynecol Oncol; 2011 Jun 01; 121(3):505-9. PubMed ID: 21420158
    [Abstract] [Full Text] [Related]

  • 5. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, Ridder R.
    Gynecol Oncol; 2017 Jan 01; 144(1):51-56. PubMed ID: 28094038
    [Abstract] [Full Text] [Related]

  • 6. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A, Frayle H, Girlando S, Sani C, Confortini M, Zorzi M, Giorgi-Rossi P, Rizzolo R, Ronco G, New Technologies for Cervical Cancer Screening Working Group.
    Int J Cancer; 2020 Oct 01; 147(7):1864-1873. PubMed ID: 32170961
    [Abstract] [Full Text] [Related]

  • 7. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M, Gotlieb W, Gilbert L, Hemmings R, Behr MA, Franco EL, STAIN-IT Study Group.
    Int J Cancer; 2021 Jan 15; 148(2):492-501. PubMed ID: 32781481
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
    Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, Wright TC.
    Int J Cancer; 2020 May 01; 146(9):2599-2607. PubMed ID: 31490545
    [Abstract] [Full Text] [Related]

  • 10. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT, Dalen I, Hansen E, Loge JL, Dybdahl BM, Dirdal MB, Moltu P, Berland JM.
    Cancer Cytopathol; 2017 Apr 01; 125(4):283-291. PubMed ID: 27918650
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL).
    Frega A, Pavone M, Sesti F, Leone C, Bianchi P, Cozza G, Colombrino C, Lukic A, Marziani R, De Sanctis L, Delli Carpini G, Caserta D, Ciavattini A.
    Eur Rev Med Pharmacol Sci; 2019 Dec 01; 23(24):10672-10677. PubMed ID: 31858534
    [Abstract] [Full Text] [Related]

  • 12. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ.
    Br J Cancer; 2014 Mar 18; 110(6):1579-86. PubMed ID: 24518601
    [Abstract] [Full Text] [Related]

  • 13. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N.
    JAMA Oncol; 2019 Feb 01; 5(2):181-186. PubMed ID: 30325982
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL, Chen W, Lei XQ, Qin Y, Wu ZN, Pan QJ, Zhang X, Chang BF, Zhang SK, Guo HQ, Qiao YL.
    Oncotarget; 2016 Apr 19; 7(16):21181-9. PubMed ID: 27029033
    [Abstract] [Full Text] [Related]

  • 15. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
    Trzeszcz M, Mazurec M, Jach R, Mazurec K, Kotkowska-Szeps I, Kania M, Wantuchowicz M, Wasowska J, Duczek-Polakiewicz M, Rozmus P, Streb J, Halon A.
    J Med Virol; 2023 Nov 19; 95(11):e29271. PubMed ID: 38009626
    [Abstract] [Full Text] [Related]

  • 16. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China.
    Song F, Yan P, Huang X, Wang C, Qu X, Du H, Wu R.
    BMC Infect Dis; 2021 Apr 30; 21(1):400. PubMed ID: 33931022
    [Abstract] [Full Text] [Related]

  • 17. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
    Koo YJ, Hahn HS, Lee IH, Lim KT, Lee KH, Kim HS, Kim TJ, Chun YK, Kim HS, Hong SR.
    Virchows Arch; 2013 Nov 30; 463(5):689-96. PubMed ID: 24081504
    [Abstract] [Full Text] [Related]

  • 18. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
    Pirtea L, Secosan C, Margan M, Moleriu L, Balint O, Grigoras D, Sas I, Horhat F, Jianu A, Ilina R.
    Bosn J Basic Med Sci; 2019 Nov 08; 19(4):336-341. PubMed ID: 29924960
    [Abstract] [Full Text] [Related]

  • 19. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
    Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, Patterson L, Govan L, Black J, Palmer T, Arbyn M.
    Cancer Epidemiol Biomarkers Prev; 2017 Nov 08; 26(11):1629-1635. PubMed ID: 28887297
    [Abstract] [Full Text] [Related]

  • 20. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study.
    White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, Sharp L, O' Toole S, Fitzpatrick M, Flannelly G, O' Leary JJ, Martin CM.
    Cytopathology; 2016 Aug 08; 27(4):269-76. PubMed ID: 26932360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.